• Here, we described a metabolic signature of acute ischemic stroke in serum by GC-MS-based metabolomics.
Introduction
Ischemic stroke (IS) remains a vexing public health problem worldwide. Neurobiological mechanisms of IS are complex; IS does not merely impair the brain, but is also harmful to peripheral organs: the bidirectional communications between the brain and peripheral organs after onset of stroke have been highlighted in patients [10] . Treatment of IS is comprehensive, and a combination therapy instead of a mono-therapy, or the incorporation of a multi-target drug has been suggested [15] . In addition, around 20% of ischemic stroke cases cannot be detected with the MRI scan technique [16] . Thus, it has given rise to an urgent need to identify some novel and easily detectable diagnostic markers of IS. As a system biology technique, metabolomics can capture the global changes and the overall pathophysiological status of diseases, which also has shown great promise in its ability to identify biomarkers of diseases [20] , and recently the technique has been used for the study of stroke clinically [11, 13, 23] . Therefore, in this study, we aimed to characterize the serum metabolic profile of acute ischemic stroke (AIS) by a gas chromatography-mass spectrometry (GC-MS)-based metabolomics technique, as well as screen the potential biomarkers and analyze the relative pathophysiological pathways of AIS.
Methods

Subjects and sample collection
The study was approved by the ethics committee of Shantou University Medical College, and a written informed consent http://dx.doi.org/10.1016/j.neulet.2017.01.039 0304-3940/© 2017 Elsevier B.V. All rights reserved. Y  4d  Y  2  8  5  28  52  F  Y  29  40  M  Y  3d  2  4  0  29  27  F  30  77  F  Y  2d  2  5  3  31  72  M  Y  3d  LBI was obtained from all subjects. Forty patients diagnosed with AIS, and 29 age and sex-matched controls, were enrolled from the First Affiliated Hospital of Shantou University Medical College. AIS was confirmed by MRI (including diffusion-weighted imaging MRI) imaging and clinical characteristics of patients, according to the recommendations of AHA/ASA [25] . Of the 40 patients, 24 cases were those of anterior circulation infarction, 12 cases were those of posterior circulation infarction, and three cases had both anterior and posterior infarction, one case was suffering from lacunar brain infarction. Most of the patients (38/40) were recruited within seven days of the onset of ischemic stroke symptoms, belonging to the acute phase of ischemic stroke (AIS). The exclusion criteria were the presence of renal and liver diseases, malignancy, autoimmune diseases, and hypothyroidism. The NIHSS score was calculated at admission and discharge to assess the severity of AIS. The basic clinical information including the subjects' gender, age and complications, was collected or evaluated during hospitalization. The detailed clinical characteristics of the subjects are described in Table 1 . The blood samples of the subjects were obtained by venipuncture after fasting overnight and collected into the blood separating gel cuvette. The serum was separated and stored at minus 80 • C for GC-MS detection. Part of the serum in each subject was directly used for conventional measurement of blood biochemical indices.
GC-MS detection
Serum was extracted with methanol as previously described [28] . To explain briefly, 100 L of serum was mixed with 900 L of a solvent mixture (methanol: H2O: 8:1, v/v), vortexed for 15 s and centrifuged at 12,000g for 10 min at 4 • C. Then 200 L of the supernatant was transferred to a GC vial, 20 L of internal standard D-norleucine (0.5 M mL −1 ) was added, mixed well and dried at 70 • C under a mild flow of pure nitrogen. Then the aliquot was oximated by adding 30 L of methoxamine hydrochloride (15 mg mL −1 ) in pyridine, and left to incubate for 16 h at room temperature. Later, 30 L of MTBSFA (1% TMCS) was added, vortexed for 30 s and kept at 37 • C for 1 h for trimethylsilylation. One L aliquot of the derivatized solution was used for GC-MS analysis.
The metabolic profiling analysis was (Table 2 ) conducted on a GC-MS system consisting of an Agilent 6890N GC system, connected to an Agilent 5975C single quadrupole MSD. A DB-5MS capillary column (Agilent, USA) was used. One L of derivatized sample was injected in splitless mode. High purity helium was used for the carrier gas at a constant flow rate of 60 mL h −1 . The GC oven temperature was programmed with an initial temperature at 60 • C for 2 min, and then increased to 285 • C at 5 • C min −1 , and maintained for 2 min. The temperature of the injection port, the transfer interface, and the EI source were set to 230 • C, 290 • C, and 230 • C, respectively. The selected mass range was set to 50−600 m/z with electron impact ionization (70 eV), and the selected scan speed was 0.99 scans per second. Each acquired chromatogram was analyzed by the ChemStation software (Agilent). Metabolites were identified using the NIST (National Institute of Standards and Technology, the version 2.0) library. Peak area of the chromatogram in every sample was normalized using the internal standard (D-norleucine) peak area.
Before detection, precision and stability were evaluated to ensure the quality of the analysis, which is similar to our previous mothod [28] .
Data processing
The GC-MS raw data were processed by the freely available software package XCMS in R language. Firstly, a CDF format file was converted from the chromatogram in each test. A txt format file was established and imported into the Umetrics SIMCA-P program version 13.0 for multivariate analysis. Partial least squares discriminant analysis (PLS-DA) was applied with unit variance (UV) scaling. The parameters of the models, such as the R 2 X, Q 2 Y, and the R 2 Y and Q 2 Y intercepts, were investigated to ensure the quality of the models, and to avoid the risk of over-fitting. T-test was performed to compare the relative amount (peak area) of identified metabolites between AIS patients and their controls in SPSS software (Chicago, IL), version 16.0. Logistic regression analysis was done to evaluate the effect of confounding factors. Mutual correlation between differential metabolites was analyzed by Pearson's correlation in SPSS. The receiver operating characteristic curve (ROC) analysis was performed by MedCalc statistical software for selecting the optimal cut-off point score for each metabolite, and to evaluate their diagnostic value. Multifactor dimensionality reduction (MDR) was used to analyze the hierarchical cluster of differential metabolites [5] . Classification and regression tree (CRT) analysis was performed to explore the most valuable metabolites for distinguishing the AIS patients from their controls [12] .
Results
Clinical characteristics of the subjects
Forty AIS patients and 29 sex-age matched controls (age, 65.7 vs. 61.0, p = 0.138; M/F, 25/15 vs. 13/16, p = 0.145) were enrolled in this study. Amongst those patients, 33 had hypertension (the controls had 14, 33/40 vs. 14/29, p = 0.004), 13 had diabetes mellitus (the controls had six, 13/40 vs. 6/29, p = 0.278). Five had additional symptoms of atrial fibrillation, and nine were aggressive. Their NIHSS scores at admission and discharge were 6.8 ± 5.2 and 5.9 ± 5.9 (paired t-test, p = 0.014), respectively.
Several serum biochemical indices were well correlated with the differential metabolites ( Table 4 ), indicating that they might participate in the global metabolic alteration of AIS. Noticeably, several inflammation-related indicators, including white blood cells (WBC), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were abnormal in the patients. The median value of WBC of all patients was 8.8 × 10 9 /L, close to a critically high value, with twelve patients having the WBC count value higher than normal value. Eighteen out of 28 detected patients had ESR values higher than normal ranges. CRP values were greater than normal ranges in all 22 detected patients. These results revealed the presence of inflammation in the bodies of the patients post IS.
Serum metabolic profile of AIS
PLS-DA plots illustrate that the AIS (Fig. 1 )patients are clearly separate from the controls, implying significant metabolic perturbations in the serum of AIS patients. In the PLS-DA model, the cumulative R 2 Y and Q 2 were 0.708 and 0.837, respectively, when two components were calculated. No over-fitting was observed according to the results of the two hundred random permutations, the R 2 Y-intercepts and Q 2 -intercepts were 0.129 and −0.324, respectively (Fig. 1S A, B) .
Differential metabolites between AIS patients and their controls
Totally, 37 metabolites were identified from the CG-MS spectrum. Of these, 17 were found significantly different between the AIS patients and the controls. Compared to the controls, the AIS patients had elevated levels of lactate, carbonate and glutamate, and lowered levels of alanine, citrate, glycine, isoleucine, leucine, serine, tyrosine, methionine, tryptophan, erythronic acid, urea, Hpurine, hypoxanthine, and proline in the serum (P < 0.05), implying a marked metabolic perturbation in AIS patients. Interestingly, the ratio of phenylalanine to tyrosine, which has been thought to be an inflammatory indicator [22] , was found to be increased in the patients. These differential metabolites were still significantly different after adjusted by diabetes mellitus and hypertension using binary logistic regression ( Table 3 ), suggesting that diabetes mellitus and hypertension did not significantly influence the comparison of metabolic profiles between the AIS patients and the controls.
According to KEGG (Kyoto Encyclopedia of Genes and Genomes), metabolic pathways related to these discriminating metabolites include, alanine, aspartate and glutamate metabolism, cysteine and methionine metabolism, glycolysis and gluconeogenesis, glutathione metabolism, branched chain amino acids catabolism, purine metabolism, glycine, serine and threonine metabolism, as well as tyrosine and tryptophan catabolism.
To investigate the latent relationship of these differential metabolites with each other, and between them and blood biochemical indices, we calculated the interactive correlation coefficients of these metabolites and indices by Pearson's correlation. As illustrated in Table 4 , most of these differential metabolites are closely correlated with each other; meanwhile, parts of the metabolites are also associated with some biochemical indices (Table 4) . These results imply that the metabolism and biochemistry changes post stroke are holistic. P-value, significance of nonparametric test; p-value a significance after adjustment for diabetes mellitus and hypertension; Fold change, ratio of metabolite's relative peak area in AIS patients to that of controls; AUC, area under the curve in the receiver operating characteristic curve (ROC) analysis; PHE/TYR, the ratio of phenylalanine to tyrosine. 
Diagnostic potential of differential metabolites in serum
Potential biomarkers of AIS were screened by the following strategies. First, ROC was implemented to evaluate the diagnostic value of the aforementioned differential metabolites. Those metabolites with the area under the curve (AUC) of more than 0.7 were selected. Second, MDR was performed to visualize the hierarchical clustering relationship between the metabolites. The result is displayed graphically in the form of an interactive dendrogram, where the vertical distance between each branch can be CRT analysis from the six core metabolites. Glycine, citrate, and methionine were filtered out, tyrosine, lactate, and tryptophan, were selected, enabling the highest precision of 91.7% to distinguish the AIS patients from their controls. taken as indicative of how similar the abundance profiles of each cluster of compounds are to each other. Six metabolites, which represented related branches respectively, were chosen to perform a CRT ( Fig. 2A) . As a result, glycine, lysine, and methionine were filtered out, while tyrosine, lactate, and tryptophan were chosen. The predicted correction percentages of the AIS patients and the controls were 97.7% and 82.8%, respectively, with an overall predicted correction percentage of 91.7%. As illustrated in Fig. 2 . B, the classifier chooses the subject score based on tyrosine to make the first split. In the left and right sub tree, the classifier then tests the rest of the subjects based on lactate. Finally, tryptophan further classifies the right sub tree.
Discussion
Ischemic stroke continues to be a major public health problem worldwide, with a poor prognosis once it occurs. Here, high-throughput GC-MS technology, coupled with multivariate statistics analysis, has provided a powerful approach to clearly separate the AIS patients from the controls and identify potential biomarkers in the serum. Serum was utilized based on the following considerations: First, serum is commonly considered to be a pool of metabolites that reflect systemic deregulation, and the markers in it could reflect the metabolic characteristics of the system during the course of AIS [26] . Second, the substance exchanges between the cerebrospinal fluid (CSF) and the blood across meningo make it possible to use the serum metabolites to represent those in the brain [10] . Third, serum is not difficult to collect in clinical practice.
Serum metabolic feature of AIS
A significant alteration of 11 amino acids (AAs) is the first noticeable metabolic characteristic in the serum of AIS patients. AAs serve a variety of biological functions; their changes might reflect some key pathophysiological pathways of AIS. Aromatic AAs includes tyrosine, phenylalanine and tryptophan, among which tyrosine and tryptophan are decreased in AIS patients. Tyrosine is a substance of catecholamine biosynthesis. After IS, brain cell injury and stress excite the sympathetic nervous system [27] , leading to a greater production of catecholamines from tyrosine. In addition, the ratio of phenylalanine to tyrosine, which can be used as an indicator of phenylalanine hydroxylase (PAH), is elevated in AIS patients, suggestive of the inhibition of PAH. After the onset of stroke, the PAH may be diminished by oxidation due to stroke-associated oxidative stress [7, 14] . Furthermore, the ratio of phenylalanine to tyrosine was so far understood to be associated with inflammation, induced by several critical conditions including a stroke [22] . Inflammation was indicated by a high value of CRP, WBC, and ESR in the patients since these three indices have been confirmed as inflammation and injury indicators [3] . Moreover, the positive correlation of CRP and WBC with NIHSS scores was found in the AIS patients, consistent with several previous reports, implying the importance of inflammation in the pathophysiological processes of AIS [6, 19] . Wherein, phenylalanine, tyrosine, and phenylalanine hydroxylase might be involved in the metabolic process of AIS-induced inflammation [22] . Tryptophan is an essential aromatic AA. Its remarkable elevation indicates that tryptophan metabolism is perturbed post onset of IS. Tryptophan is the precursor of serotonin, an important inhibitory neurotransmitter. The latter has been observed to be at a declined level in AIS patients, exerting neurotoxic effects [21] . Thus, the increase of tryptophan in the serum after the onset of IS may be a consequence of neurotoxicity, presenting as a lowered serotonin biosynthesis from tryptophan. Glutamate obviously increases in AIS patients. As a nerve excitatory AA, glutamate is an indicator of neural excitation and neurotoxin, and is found to be positively associated with an enlargement of infarction [1, 17] . Excessive glutamate releases can trigger numerous catastrophic signaling cascades, accelerating neuronal death and exacerbating cerebral injuries during AIS [2] . As a nerve inhibitory amino acid, glycine is significantly diminished in AIS patients, contrary to glutamate. It might also be a consequence of neural excitation during brain ischemia and injury, in which the release of glycine may be inhibited. Glycine supplementation to protect neuronal cells after brain ischemia has been proposed in a clinical setting [8] . Branchedchain amino acids (BCAAs) include valine, leucine, and isoleucine, of which leucine and isoleucine show a remarkable decline in the serum of AIS patients. The result is consistent with a previous study discovering lowered plasma BCAAs levels both in a rat stroke model and in AIS patients [13] . The cause and significance of BCAA reduction in AIS patients are not clear. However, BCAAs are found to be lowered below normal levels in several critical illnesses, such as sepsis, trauma, brain injury, and heart diseases [9, 13] , which suggests a key role of these AAs in bioenergetics homeostasis, and its detrimental influence on the human body, due to the BCAAs disturbance post IS.
In addition to AAs metabolism, energy-related metabolism is also perturbed by IS. First, glycolysis is enhanced and tricarboxylic acid cycle (TAC) is inhibited, as is indicated by an elevated level of lactate, and a lowered level of citrate in AIS patients. Lactate is an indicator of ischemia and its successive hypoxia or anoxia, and has been found to be abnormally elevated in the CSF, brain tissues, and the serum of AIS patients. Lactate is also found to be related to neuronal cell death and to the prognosis of IS [4, 18] . The current study further confirms the elevation of serum lactate from the perspective of metabolomics.
Diagnostic potential of differential metabolites
Given the complexity of neurobiological mechanisms of ischemic stroke, it might not be surprising that a combination, rather than a single metabolite, would be needed to confirm AIS. After multiple screening processes, tyrosine, lactate, and tryptophan are proved to be a panel of potential biomarkers, yielding a high precision (91.7%) to diagnose AIS. CRT analysis demonstrates that, to accurately diagnose AIS or discriminate AIS patients from their controls, we should first detect tyrosine, and then lactate and tryptophan in succession. In addition, the ratio of phenylalanine to tyrosine are found to dramatically increase in AIS patients, which also displays a high precision (with AUC of 0.952) to diagnoseAIS. Although implying the existence of ischemia, the current AIS potential biomarkers are different from those of ischemia caused by other pathophysiological processes especially myocardial ischemia [24] . The reasons may be that these potential biomarkers represent some more pathophysiological processes other than ischemia, such as nerve excitation, neurotoxicity, and neural injury.
Limitations
The current findings are preliminary, which need to be further validated in another independent sample. Therefore, it is our endeavor to recruit more subjects to add to the current sample lot, to make them ideally matched in the sex and age ratio in the following studies.
Conclusions
In this study, we discovered a novel serum metabolic feature of AIS, with AAs being the most important disturbed metabolites. The metabolic signature reflects pathophysiological processes of inflammation, energy deficit, oxidative stress, neurotoxicity, nerve excitation, and neural injury. Tyrosine, lactate, and tryptophan are considered to be a panel of potential biomarkers of AIS. The current findings could provide insight into pathophysiological mechanisms of IS, and might offer new diagnostic markers and therapeutic targets for IS.
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